拓扑替康及其联合化疗对卵巢癌细胞系3AO及耐药系3AO/cDDP作用的实验研究  

Experimental study of the role of topotecan and topotecan based-combination chemotherapy to human ovarian epithelial carcinoma cell line 3AO and its cis-platinum-resistant cell line 3AO/cDDP.

作　　者：刘培淑[1] 延俊元[1] 侯萍[1] 李爱华[1] 

机构地区：[1]山东大学齐鲁医院,济南250012

出　　处：《现代妇产科进展》2002年第4期255-257,共3页Progress in Obstetrics and Gynecology

摘　　要：目的 :探讨拓扑替康 (Topotecan ,TPT)及联合化疗对卵巢癌细胞系的治疗效果。方法 :将TPT单用或与 3种临床上常用的卵巢上皮癌化疗药物顺铂 (cDDP)、卡铂(CBP)、VP 16合用 ,观察人卵巢上皮癌 (OEC)细胞系 3AO及其顺铂耐药细胞系 3AO/cDDP的生长抑制率及耐药指数 ,药物敏感试验采用MTT法。结果 :3AO对cDDP最为敏感 (P<0 .0 1) ;CBP +TPT对 3AO的作用优于其他方案 (P <0 .0 5 )。 3AO/cDDP对cDDP耐药 ,对CBP的耐药性也较强 ,而对TPT较为敏感 (P <0 .0 1)。cDDP、VP 16与TPT联合化疗对3AO/cDDP的抑制率最强。结论 :TPT对人卵巢癌细胞系 3AO和顺铂耐药细胞系 3AO/cDDP具有较好的抑制作用 ,可以作为临床上初发和复发OEC的化疗药物 。Objective:To investigate effection of topotecanand topotecan based combination chemotherapy to the human ovarian cancercell line in vitro.Methods:Using cultured human ovarian cancer cell line 3AO andits cis platinum resistance cell line 3AO/cDDP in vitro,the sensitivity test of cDDP,VP 16 and TPT which were frenquently used in chemotherapy was carried out using MTT assay to observe the IR and RI and evaluete the feasibility of TPT in primary and recurrent OEC.Results: CDDP was the most sensitive drug to 3AO in ordinary dose(P<0.01);CBP plus TPT was superior to others(P<0.05).3AO/cDDP maintained its resistance to cDDP and had resistance to CBP,but it was sensitive to TPT(P<0.01).The combination of TPT,cDDPand VP 16 had the strongest inhibition to the cell line 3AO/cDDP. Conclusions:TPT has strong inhibition to the human ovarian cancer line 3AO,3AO/cDDP,so it can be used as the principle chemotherapy drug to OEC.

关 键 词：联合化疗 DNA拓扑异构酶I 拓扑替康 药物疗法 卵巢肿瘤 药物敏感试验 

分 类 号：R737.310.5[医药卫生—肿瘤]